Faculty Bibliography

Treating HIV before it causes symptoms might delay its progression to AIDS but doesn't prolong a patient's survival, a new study says. The study Saturday in the Brit ish Medical Journal supports findings from a 1993 study in Europe that also called into question a standard practice of prescribing the drug AZT for people infected with HIV, the human immunodeficiency virus that causes AIDS. The authors of the new British study said they hoped it will raise more discussion about the relative merits of treating HIV early or after symptoms develop and stimulate scientists to focus more studies on the quality of life among those treated for HIV

The study, reported Saturday in the British Medical Journal, supports findings from the Concorde study in Europe that in 1993 called into question a standard practice of prescribing the drug AZT for people infected with HIV, or human immunodeficiency virus, which causes AIDS. The British study involved 436 AIDS patients at St. Mary's Hospital Medical School in London. Its authors said they hoped it would raise more discussion about the relative merits of treating HIV early or after symptoms develop and stimulate scientists to focus more studies on the quality of life among those treated for HIV-infection

Treatment of HIV infection before it causes symptoms may delay progression to AIDS but does not prolong survival, a new study has found. The study, reported Saturday in the British Medical Journal, supports findings from the Concorde study in Europe that in 1993 called into question a standard practice of prescribing the drug AZT for people infected with HIV, or human immunodeficiency virus, which causes AIDS. The British study involved 436 AIDS patients at St. Mary's Hospital Medical School in London. Its authors said they hoped it would raise more discussion about the relative merits of treating HIV early or after symptoms develop and stimulate scientists to focuson the quality of life among those treated for HIVinfection

Treatment of HIV infection before it causes symptoms may delay its progression to AIDS but does not prolong survival, a new study reported on Jul 15, 1995 in the British Medical Journal has found

WASHINGTON - Treatment of HIV infection before it causes symptoms may delay progression to AIDS but does not prolong survival, a new study has found. The study, reported yesterday in the British Medical Journal, supports findings from the Concorde study in Europe that in 1993 called into question a standard practice of prescribing the drug AZT for people infected with HIV, or human immunodeficiency virus, which causes AIDS. The British study involved 436 AIDS patients at St. Mary's Hospital Medical School in London

Treatment of HIV infection before it causes symptoms may delay progression to AIDS but does not prolong survival, a new study has found. The study, reported Saturday in the British Medical Journal, supports findings from the Concorde study in Europe that in 1993 called into question a standard practice of prescribing the drug AZT for people infected with HIV, or human immunodeficiency virus, which causes AIDS. The British study involved 436 AIDS patients at St. Mary's Hospital Medical School in London. Its authors said they hoped it would raise more discussion about the relative merits of treating HIV early or after symptoms develop and stimulate scientists to focus more studies on the quality of life among those treated for HIV infection

An advisory panel to the Food and Drug Administration unanimously recommended Friday that one AIDS patient be allowed to receive an experimental bone marrow transplant from a baboon. Baboons are naturally resistant to HIV-1, the virus that is causing the overwhelming majority of AIDS cases in the world. The underlying aim of the experiment is to determine whether uninfected baboon cells will join the HIV-infected human marrow to restore the body's immune function. 'We're ready to go,' the advisory committee was told by Dr. Steven Deeks, an investigator at UC San Francisco, where the experiment will be carried out. The timing of the experiment will depend in part on when the investigators provide the FDA with additional data and when local ethics and bio-safety committees in San Francisco give final approval

An advisory panel to the Food and Drug Administration unanimously recommended Friday that one AIDS patient be allowed to receive an experimental bone marrow transplant from a baboon. Baboons are naturally resistant to HIV-1, the virus that is causing the overwhelming majority of AIDS cases in the world. The underlying aim of the experiment is to determine whether uninfected baboon cells will join the HIV-infected human marrow to restore the body's immune function. After the vote, two FDA officials said they expected the agency to approve the experiment after the researchers from the University of Pittsburgh and the University of California at San Francisco provide additional data

According to a report issued on Jul 13, 1995 by the Institute of Medicine of the National Academy of Sciences, new steps are needed to prevent the disastrous spread of another dangerous infectious agent like HIV in the nation's blood supply. The report said the ability of the US's blood banking and public systems to identify and guard against unknown microbes is weak